Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTSV NASDAQ:INSM NASDAQ:IRWD NASDAQ:PCRX NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$163.94+1.0%$139.14$60.40▼$166.44$34.31B1.032.20 million shs1.46 million shsIRWDIronwood Pharmaceuticals$1.48-6.6%$1.26$0.53▼$5.13$257.46M0.31.39 million shs1.07 million shsPCRXPacira BioSciences$22.26-0.4%$25.42$15.92▼$27.64$1.00B0.4538,003 shs498,421 shsZYMEZymeworks$18.11+0.3%$15.27$9.03▼$18.49$1.36B1.51542,646 shs479,857 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed0.00%+3.29%+11.24%+59.32%+117.72%IRWDIronwood Pharmaceuticals0.00%+2.26%+20.99%+114.74%-62.79%PCRXPacira BioSciences0.00%-10.02%-17.59%-4.12%+37.79%ZYMEZymeworks0.00%+6.61%+14.74%+35.28%+36.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$163.94+1.0%$139.14$60.40▼$166.44$34.31B1.032.20 million shs1.46 million shsIRWDIronwood Pharmaceuticals$1.48-6.6%$1.26$0.53▼$5.13$257.46M0.31.39 million shs1.07 million shsPCRXPacira BioSciences$22.26-0.4%$25.42$15.92▼$27.64$1.00B0.4538,003 shs498,421 shsZYMEZymeworks$18.11+0.3%$15.27$9.03▼$18.49$1.36B1.51542,646 shs479,857 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed0.00%+3.29%+11.24%+59.32%+117.72%IRWDIronwood Pharmaceuticals0.00%+2.26%+20.99%+114.74%-62.79%PCRXPacira BioSciences0.00%-10.02%-17.59%-4.12%+37.79%ZYMEZymeworks0.00%+6.61%+14.74%+35.28%+36.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTSVForty Seven 0.00N/AN/AN/AINSMInsmed 2.86Moderate Buy$149.06-9.07% DownsideIRWDIronwood Pharmaceuticals 2.25Hold$4.94233.78% UpsidePCRXPacira BioSciences 2.43Hold$33.4050.04% UpsideZYMEZymeworks 2.91Moderate Buy$22.5024.24% UpsideCurrent Analyst Ratings BreakdownLatest INSM, PCRX, FTSV, ZYME, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ZYMEZymeworksB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.0010/8/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/6/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/3/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $196.0010/2/2025INSMInsmedCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/2/2025INSMInsmedTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$154.00 ➝ $193.0010/1/2025INSMInsmedEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$180.009/27/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70INSMInsmed$363.71M95.28N/AN/A$1.60 per share102.46IRWDIronwood Pharmaceuticals$351.41M0.68$0.05 per share32.04($1.88) per share-0.79PCRXPacira BioSciences$700.97M1.43$4.30 per share5.18$16.86 per share1.32ZYMEZymeworks$122.87M11.08N/AN/A$6.63 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AINSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)IRWDIronwood Pharmaceuticals$880K-$0.05N/A5.92N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A8.66N/A-18.08%13.29%6.61%11/5/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest INSM, PCRX, FTSV, ZYME, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025IRWDIronwood Pharmaceuticals$0.08N/AN/AN/A$74.22 millionN/A11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A10/30/2025Q3 2025INSMInsmed-$1.35N/AN/AN/A$114.33 millionN/A10/30/2025N/AZYMEZymeworks-$0.28N/AN/AN/AN/AN/A8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTSVForty SevenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTSVForty SevenN/A14.8114.81INSMInsmed0.456.686.33IRWDIronwood PharmaceuticalsN/A0.820.82PCRXPacira BioSciences0.502.381.91ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTSVForty Seven71.77%INSMInsmedN/AIRWDIronwood PharmaceuticalsN/APCRXPacira BioSciences99.73%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipFTSVForty Seven37.40%INSMInsmed3.00%IRWDIronwood Pharmaceuticals12.70%PCRXPacira BioSciences6.40%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTSVForty Seven5748.16 millionN/ANot OptionableINSMInsmed1,271211.38 million205.03 millionOptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableZYMEZymeworks46075.17 million67.56 millionOptionableINSM, PCRX, FTSV, ZYME, and IRWD HeadlinesRecent News About These CompaniesZymeworks Inc.: Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ...4 hours ago | finanznachrichten.deZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International Conference4 hours ago | tmcnet.comZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceOctober 13 at 4:00 PM | globenewswire.comZymeworks (NYSE:ZYME) Stock Price Up 7.2% - Here's What HappenedOctober 11 at 11:45 AM | marketbeat.comEquities Analysts Set Expectations for Zymeworks Q3 EarningsOctober 11 at 2:19 AM | americanbankingnews.comLifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)October 10 at 7:27 AM | marketbeat.comZymeworks appoints Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | msn.comInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | globenewswire.comWhy Analysts See the Zymeworks Story Evolving After Key Pipeline and Market MovesOctober 8, 2025 | finance.yahoo.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalOctober 8, 2025 | marketbeat.comPlatinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYMEOctober 2, 2025 | marketbeat.comBrokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $21.43October 2, 2025 | americanbankingnews.comVoya Investment Management LLC Sells 43,861 Shares of Zymeworks Inc. $ZYMEOctober 1, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 29, 2025 | marketbeat.comBloom Burton Remains a Buy on Zymeworks (ZYME)September 21, 2025 | theglobeandmail.comRhumbline Advisers Sells 21,138 Shares of Zymeworks Inc. $ZYMESeptember 21, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, PCRX, FTSV, ZYME, and IRWD Company DescriptionsForty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Insmed NASDAQ:INSM$163.94 +1.61 (+0.99%) Closing price 04:00 PM EasternExtended Trading$164.50 +0.56 (+0.34%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Ironwood Pharmaceuticals NASDAQ:IRWD$1.48 -0.11 (-6.62%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.06 (+4.05%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Pacira BioSciences NASDAQ:PCRX$22.26 -0.09 (-0.40%) Closing price 04:00 PM EasternExtended Trading$22.02 -0.24 (-1.06%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Zymeworks NYSE:ZYME$18.11 +0.05 (+0.28%) Closing price 04:00 PM EasternExtended Trading$18.04 -0.07 (-0.41%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
